Vical Gets $2.3M for Phase 3 Trial

Bruce V. Bigelow2/11/09

San Diego’s Vical (NASDAQ: VICL), which specializes in developing DNA vaccines, says it received a $2.3 million payment from Japan’s AnGes MG to continue its work on a phase 3 trial of its Allovectin-7 vaccine for metastatic melanoma. Vical says it has received $17.6 million in total payments so far out of $22.6 million that AnGes pledged under their development agreement. Vical has been developing a variety of DNA vaccines, in which the expressed protein is an immunogen, immune system stimulant, or in the case of cardiovascular therapy, an angiogenic growth factor.

Bruce V. Bigelow is the editor of Xconomy San Diego. You can e-mail him at bbigelow@xconomy.com or call (619) 669-8788